Dimensional Fund Advisors LP Lowers Stock Position in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Dimensional Fund Advisors LP lowered its position in Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 1.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,371,725 shares of the life sciences company's stock after selling 32,124 shares during the quarter. Dimensional Fund Advisors LP owned about 3.07% of Integra LifeSciences worth $53,790,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Nordea Investment Management AB grew its stake in shares of Integra LifeSciences by 4.1% in the 4th quarter. Nordea Investment Management AB now owns 127,908 shares of the life sciences company's stock valued at $2,919,000 after buying an additional 5,032 shares during the period. Romano Brothers AND Company acquired a new position in Integra LifeSciences in the fourth quarter valued at approximately $204,000. Mitsubishi UFJ Asset Management UK Ltd. purchased a new position in Integra LifeSciences in the fourth quarter worth approximately $204,000. Nisa Investment Advisors LLC increased its stake in Integra LifeSciences by 599.6% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company's stock worth $74,000 after acquiring an additional 2,800 shares during the last quarter. Finally, Choreo LLC raised its position in Integra LifeSciences by 29.9% in the fourth quarter. Choreo LLC now owns 22,274 shares of the life sciences company's stock valued at $500,000 after purchasing an additional 5,123 shares during the period. 84.78% of the stock is currently owned by institutional investors and hedge funds.

Integra LifeSciences Stock Down 4.0 %

IART traded down $0.53 on Tuesday, reaching $12.75. The company's stock had a trading volume of 2,558,672 shares, compared to its average volume of 1,073,279. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79. Integra LifeSciences Holdings Co. has a fifty-two week low of $11.60 and a fifty-two week high of $32.66. The stock has a 50 day moving average of $19.73 and a two-hundred day moving average of $22.09. The company has a market capitalization of $984.94 million, a price-to-earnings ratio of -141.65, a P/E/G ratio of 0.73 and a beta of 1.27.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The life sciences company reported $0.41 earnings per share for the quarter, missing analysts' consensus estimates of $0.43 by ($0.02). The company had revenue of $382.65 million during the quarter, compared to analysts' expectations of $381.17 million. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. Integra LifeSciences's revenue was up 3.7% on a year-over-year basis. During the same period last year, the firm earned $0.55 earnings per share. As a group, analysts forecast that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on IART. JPMorgan Chase & Co. lowered their price target on Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating for the company in a report on Tuesday. Argus raised shares of Integra LifeSciences from a "hold" rating to a "buy" rating in a research report on Monday, March 31st. Truist Financial dropped their price objective on shares of Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating for the company in a report on Friday, April 11th. Finally, Wells Fargo & Company reduced their target price on shares of Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating on the stock in a report on Tuesday. Four investment analysts have rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the company's stock. Based on data from MarketBeat.com, Integra LifeSciences currently has a consensus rating of "Hold" and an average target price of $19.88.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.